Last reviewed · How we verify
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Mild Cognitive Impairment Patients With Cerebrovascular Disease
This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV Trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in Mild Cognitive Impairment Patients with Cerebrovascular Disease
Details
| Lead sponsor | Chong Kun Dang Pharmaceutical |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 418 |
| Start date | 2021-09 |
| Completion | 2024-11 |
Conditions
- Vascular Cognitive Impairment
Interventions
- Choline Alfoscerate 400mg
- Placebo of Choline Alfoscerate 400mg
Primary outcomes
- The proportion of subjects whose cognitive function is maintained/improved at 48 weeks compared to baseline — Baseline to 48 weeks
Countries
South Korea